These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

691 related articles for article (PubMed ID: 22042970)

  • 21. N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer.
    Mease RC; Dusich CL; Foss CA; Ravert HT; Dannals RF; Seidel J; Prideaux A; Fox JJ; Sgouros G; Kozikowski AP; Pomper MG
    Clin Cancer Res; 2008 May; 14(10):3036-43. PubMed ID: 18483369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting Prostate-Specific Membrane Antigen (PSMA) with F-18-Labeled Compounds: the Influence of Prosthetic Groups on Tumor Uptake and Clearance Profile.
    Bouvet V; Wuest M; Bailey JJ; Bergman C; Janzen N; Valliant JF; Wuest F
    Mol Imaging Biol; 2017 Dec; 19(6):923-932. PubMed ID: 28639122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Effects of Monosodium Glutamate on PSMA Radiotracer Uptake in Men with Recurrent Prostate Cancer: A Prospective, Randomized, Double-Blind, Placebo-Controlled Intraindividual Imaging Study.
    Harsini S; Saprunoff H; Alden T; Mohammadi B; Wilson D; Bénard F
    J Nucl Med; 2021 Jan; 62(1):81-87. PubMed ID: 32385167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor Uptake of Triazine Dendrimers Decorated with Four, Sixteen, and Sixty-Four PSMA-Targeted Ligands: Passive versus Active Tumor Targeting.
    Lim J; Guan B; Nham K; Hao G; Sun X; Simanek EE
    Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31466360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.
    Dietlein M; Kobe C; Kuhnert G; Stockter S; Fischer T; Schomäcker K; Schmidt M; Dietlein F; Zlatopolskiy BD; Krapf P; Richarz R; Neubauer S; Drzezga A; Neumaier B
    Mol Imaging Biol; 2015 Aug; 17(4):575-84. PubMed ID: 26013479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Prospective Study on
    Rousseau E; Wilson D; Lacroix-Poisson F; Krauze A; Chi K; Gleave M; McKenzie M; Tyldesley S; Goldenberg SL; Bénard F
    J Nucl Med; 2019 Nov; 60(11):1587-1593. PubMed ID: 30979820
    [No Abstract]   [Full Text] [Related]  

  • 27. A low molecular weight PSMA-based fluorescent imaging agent for cancer.
    Chen Y; Dhara S; Banerjee SR; Byun Y; Pullambhatla M; Mease RC; Pomper MG
    Biochem Biophys Res Commun; 2009 Dec; 390(3):624-9. PubMed ID: 19818734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates.
    Banerjee SR; Foss CA; Pullambhatla M; Wang Y; Srinivasan S; Hobbs RF; Baidoo KE; Brechbiel MW; Nimmagadda S; Mease RC; Sgouros G; Pomper MG
    J Nucl Med; 2015 Apr; 56(4):628-34. PubMed ID: 25722448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective intraindividual comparison of 18F-PSMA-7Q and 18F-DCFPyL PET/CT in patients with newly diagnosed prostate cancer.
    Liu Y; Zhang X; Liu J; Zhang J; Xu B
    Nucl Med Commun; 2022 Jun; 43(6):725-730. PubMed ID: 35560134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intra-individual comparison of
    Ferreira G; Iravani A; Hofman MS; Hicks RJ
    Cancer Imaging; 2019 May; 19(1):23. PubMed ID: 31092293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer.
    Chen Y; Foss CA; Byun Y; Nimmagadda S; Pullambhatla M; Fox JJ; Castanares M; Lupold SE; Babich JW; Mease RC; Pomper MG
    J Med Chem; 2008 Dec; 51(24):7933-43. PubMed ID: 19053825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peripheral ganglia in healthy rats as target structures for the evaluation of PSMA imaging agents.
    Endepols H; Morgenroth A; Zlatopolskiy BD; Krapf P; Zischler J; Richarz R; Muñoz Vásquez S; Neumaier B; Mottaghy FM
    BMC Cancer; 2019 Jun; 19(1):633. PubMed ID: 31242896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate-Specific Membrane Antigen-Targeted Imaging With [18F]DCFPyL in High-Grade Gliomas.
    Salas Fragomeni RA; Menke JR; Holdhoff M; Ferrigno C; Laterra JJ; Solnes LB; Javadi MS; Szabo Z; Pomper MG; Rowe SP
    Clin Nucl Med; 2017 Oct; 42(10):e433-e435. PubMed ID: 28737579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and positron emission tomography evaluation of
    Fan W; Zhang Z; Zhu Z; Yang D; Chen X; Wang J; Chen F; Song X
    Oncol Lett; 2015 Oct; 10(4):2299-2302. PubMed ID: 26622838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repeatability of Quantitative
    Jansen BHE; Cysouw MCF; Vis AN; van Moorselaar RJA; Voortman J; Bodar YJL; Schober PR; Hendrikse NH; Hoekstra OS; Boellaard R; Oprea-Lager DE
    J Nucl Med; 2020 Sep; 61(9):1320-1325. PubMed ID: 31924729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen.
    Kiess AP; Minn I; Chen Y; Hobbs R; Sgouros G; Mease RC; Pullambhatla M; Shen CJ; Foss CA; Pomper MG
    J Nucl Med; 2015 Sep; 56(9):1401-1407. PubMed ID: 26182968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined model-based and patient-specific dosimetry for
    Plyku D; Mena E; Rowe SP; Lodge MA; Szabo Z; Cho SY; Pomper MG; Sgouros G; Hobbs RF
    Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):989-998. PubMed ID: 29460025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison between
    Liu Y; Dong Y; Liu J; Zhang X; Lin M; Xu B
    Prostate; 2021 Dec; 81(16):1329-1336. PubMed ID: 34516670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In Vitro and In Vivo Characterization of an
    Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S
    J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.